PATENT CLAIM ANALYSIS

Application Number: 16240368
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-05
Patent Classification: ["514", "374000"]

Abstract:
The present invention is directed to methods of treating and/or ameliorating muscular dystrophy and/or treating cardiomyopathy in muscular dystrophy patients by administration of a therapeutically effective amount of a thromboxane A 2  receptor antagonist.

Claim (Index 21):
The method of  claim 1 , wherein the thromboxane A 2  receptor antagonist is administered orally once per day.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 99.0
- Lexical Diversity: 1.25
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15592727', '14715143', '16004666', '15608507', '14391484']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8030284629207711
- 35 USC 102 Novelty (BERT): 0.684747219564733
- Combined Prediction Score: 0.7912003385851674
- Mean Citation Score: 474.704658
- Max Citation Score: 725.87805
- Similarity Product: 649.9765074764014

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test